Company Overview and News

 
Here's Why Investors Should Steer Clear of Adtalem (ATGE)

2018-10-10 zacks
In order to maximize portfolio returns, one must get rid of stocks that can be damaging to the portfolio. One such stock could be Adtalem Global Education Inc. (ATGE - Free Report) , which has been witnessing weak enrollments at its institutions. Though the company’s shares have gained 32.7% in a year against the industry’s decline of 24.8%, the stock’s past-three-month performance shows a decline of 10.
ABCD BPI ATGE LAUR

23
6 Stocks Set for Monster Growth in 2019

2018-10-06 investorplace - 2
Although stocks have experienced a rough start so far in 2018, some stocks still have a big chance to shine this year. The best stocks to buy now go above and beyond the normal growth prospects. While looking for these kinds of investments, I examined six of the best stocks to invest in, all with huge upside potential and support from the Street’s top analysts.
CBS CLDR CBS.A NBIX PLAY CPV CBS.WD SBGI LAUR

 
LAUR / LAUREATE EDUCATION, INC. 8-K/A (Current Report)

2018-09-13 sec.gov
Document UNITED STATES
LAUR

 
Laureate Education to Present at BMO Capital Markets 18th Annual Back to School Conference

2018-09-06 globenewswire
BALTIMORE, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Laureate Education, Inc. (NASDAQ: LAUR), the global leader in higher education, today announced that the Company will participate in BMO Capital Markets 18th Annual Back to School Conference on September 13, 2018 at the InterContinental Barclay Hotel in New York.
BEAV LAUR

23
7 Stocks Set for Monster Growth in 2018

2018-08-30 investorplace - 2
Although stocks have experienced a rough start so far in 2018, some stocks still have a big chance to shine this year. The best stocks to buy now go above and beyond the normal growth prospects. While looking for these kinds of investments, I examined seven of the best stocks to invest in, all with huge upside potential and support from the Street’s top analysts.
CBS ARNA CLDR CBS.A NBIX PLAY CPV CBS.WD SBGI LAUR

 
Laureate Education (LAUR) CEO Eilif Serck-Hanssen on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good morning and welcome to the Second Quarter 2018, Laureate Education Incorporated Earnings Conference Call. My name is Brandon and I’ll be your operator for today. At this time all participants are in a listen-only mode. [Operator Instructions]. Please note, this conference is being recorded.
LAUR

 
LAUR / LAUREATE EDUCATION, INC. 10-Q (Quarterly Report)

2018-08-09 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LAUR

1
LAUR / LAUREATE EDUCATION, INC. 8-K (Current Report)

2018-08-09 sec.gov - 1
UNITED STATES
LAUR

1
LAUR / LAUREATE EDUCATION, INC. 8-K (Current Report)

2018-07-20 sec.gov - 1
Document UNITED STATES
LAUR

4
4 Factors That Underscore Strayer's (STRA) Solid Prospects

2018-07-10 zacks
Strayer Education Inc.’s (STRA - Free Report) shares have been on the move in the recent times, rallying 32.1% year to date, faring much better than the industry’s growth of just 4.8%. In fact, this for-profit education company has gained 6.5% in the past 30 days against the industry’s 10.6% decline. Also, the company has outperformed the industry in all the other time frames that we considered — 4-week, 12-week and 52-week.
APEI LRN STRA LAUR

14
GDS Announces Changes to Board of Directors

2018-06-22 globenewswire
SHANGHAI, China, June 22, 2018 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings,” “GDS” or the “Company”) (NASDAQ:GDS), a leading developer and operator of high-performance data centers in China, today announced, effective immediately, that Mr. Erik Siao, independent director of the board of directors (“Board”) and member of the audit committee, resigned from the Board for personal reasons.
CBB CONE GDS LAUR

81
7 Stocks Set for Monster Growth in 2018

2018-06-04 investorplace - 5
Although stocks have experienced a rough start so far in 2018, some stocks still have a big chance to shine this year. Such stocks go above and beyond the normal growth prospects. While looking for these kinds of stocks, I examined seven top growth stocks with huge upside potential and serious Street support.
CBS ARNA CLDR CBS.A NBIX PLAY CPV CBS.WD SBGI LAUR

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to LAUR / LAUREATE EDUCATION, INC. on message board site Silicon Investor.

Ronald S Laura Enterprises (OTC BB: BFIT) Ronald S Laura Enterprises (OTC BB: BFIT) Ronald S Laura Enterprises (OTC BB: BFIT) Polo, Ralph Lauren (RL) Polo, Ralph Lauren (RL) Polo, Ralph Lauren (RL)
CUSIP: 518613203